| 
         
          | Traditional 
              Risk Factors Predict Cardiovascular Risk in People with HIV
              
              
                
                 
                  |  |  |  |  |  |   
                  |  |  | 
                       
                        | SUMMARY: 
                          Traditional 
                          risk factors including male sex, family history, smoking, 
                          abnormal blood lipids, and high blood pressure were 
                          among the predictors of atherosclerosis and cardiovascular 
                          events in 2 recently published studies. One analysis 
                          found that certain inflammation biomarkers were associated 
                          with elevated risk, and the other observed that use 
                          of tenofovir 
                          (Viread, also in the Truvada 
                          and Atripla 
                          coformulations) might actually have a protective effect, 
                          but neither saw a link between cardiovascular disease 
                          and lower CD4 cell count. |  |  |  |   
                  |  |  |  |  |  |  By 
                Liz Highleyman
 Several studies have shown that people 
                with HIV have a higher risk of cardiovascular disease and 
                associated events such as heart attacks compared with the HIV 
                negative general population. It is not yet clear, however, whether 
                this is due to HIV infection itself, chronic immune activation 
                and inflammation, antiretroviral 
                drugs, a higher prevalence of traditional risk factors, or 
                some combination of these.
 FRAM 
                Study As 
                described in the September 
                10, 2010 issue of AIDS, Joseph Delaney, Carl Grunfeld, 
                and fellow investigators with the Fat Redistribution and Metabolic 
                Change in HIV (FRAM) study looked at an early indicator of cardiovascular 
                disease, carotid intima-media thickness (IMT).   Increased 
                carotid IMT -- or greater thickness of the lining of the carotid 
                arteries supplying blood to the brain -- is a sign of atherosclerosis, 
                or buildup of plaque and loss of elasticity in the arteries. Atherosclerosis 
                of the coronary arteries supplying the heart can lead to a heart 
                attack, while carotid atherosclerosis is a risk factor for strokes. 
 The FRAM team aimed to identify HIV-related risk factors associated 
                with increased carotid IMT, including CD4 T-cell count, HIV viral 
                load, and use of antiretroviral therapy (ART).
 
 This retrospective analysis looked at medical records from 538 
                HIV positive FRAM participants. A majority (about 70%) were men, 
                about 40% were African-American, the mean age was 48 years, and 
                the average estimated duration of HIV infection was 13 years; 
                almost all were on combination ART. With regard to traditional 
                cardiovascular risk factors, more than half were current or former 
                smokers.
 
 All participants had at least 1 carotid artery ultrasound scan. 
                The researchers focused on IMT in the common carotid (the main 
                segment of the artery before it forks into 2 branches), the internal 
                carotid (1 of the 2 branches), and the carotid bulb (the bulging 
                segment around the bifurcation where the artery forks); prior 
                research has shown that the 
                site of measurement can affect likelihood of detecting carotid 
                artery thickening.
 
 Results
 
                 
                  |  | In 
                    a Bayesian mathematical model, predictors of increased IMT 
                    in the common carotid artery included: |   
                  |  | 
                       
                        |  | Older 
                          age, black race, systolic and diastolic blood pressure: 
                          all at least 95% probability; |   
                        |  | Lower 
                          high-density lipoprotein (HDL) "good" cholesterol: 
                          85% probability; |   
                        |  | Hispanic 
                          ethnicity: 51% probability. |  |   
                  |  | Of 
                    all the HIV-related factors included in the analysis, only 
                    tenofovir use was a significant predictor (51% probability), 
                    but it was associated with decreased IMT (-0.0094 mm per year 
                    of use). |   
                  |  | Predictors 
                    of increased internal carotid IMT included older age and smoking 
                    (both 100% probability). |   
                  |  | For 
                    internal carotid IMT there were no HIV-related risk factors 
                    above the 50% probability threshold. |  "We 
                observed an inverse association between duration of tenofovir 
                use and common carotid IMT," the study authors concluded. 
                "Whether this association is causal or due to confounding 
                by indication needs further investigation."
 The investigators were unable to explain the apparent modest protective 
                effect of tenofovir. Participants taking this drug had similar 
                demographic characteristics, somewhat lower total cholesterol, 
                but a history of worse HIV disease (lower nadir CD4 cell count, 
                higher percentage with an AIDS diagnosis).
 
 Inflammation Biomarkers
 
 In the second study, described in the June 
                19, 2010 issue of AIDS, Emily Ford from the National Institute 
                of Allergy and Infectious Diseases (NIAID) and colleagues performed 
                a retrospective case-control study to assess the association between 
                cardiovascular events and traditional cardiovascular risk factors, 
                HIV disease, and inflammation.
 
 A growing body of evidence indicates that chronic immune activation 
                and persistent inflammation contribute to several non-AIDS conditions 
                -- including cardiovascular disease and non-AIDS cancers -- seen 
                with increasing frequency as people with HIV survive longer due 
                to effective ART.
 
 This analysis included HIV positive participants enrolled in National 
                Institutes of Health clinical protocols between 1995 and 2009. 
                A total of 52 individuals who experienced an incident (new) cardiovascular 
                disease event (for example, a heart attack) were matched 2:1 with 
                HIV positive people without cardiovascular disease.
 
 The researchers measured several biomarkers of inflammation and 
                immune cell activation in blood serum or plasma and in peripheral 
                blood mononuclear cells. These included the acute phase inflammation 
                marker high-sensitivity C-reactive protein (CRP), the coagulation 
                (thrombosis or clotting) biomarker D-dimer, the endothelial dysfunction 
                marker soluble vascular cell adhesion molecule-1 (VCAM-1), and 
                tissue inhibitor of metalloproteinase-1 (TIMP-1).
 
 Results
 
                 
                  |  | The 
                    52 case patients with cardiovascular events were significantly 
                    more likely to have traditional risk factors compared with 
                    control subjects, either at baseline or after up to 2 years 
                    of follow-up: |   
                  |  | 
                       
                        |  | Smoking: 
                          49% among cases vs 25% among controls; |   
                        |  | Family 
                          history of cardiovascular disease: 30% vs 11%, respectively; |   
                        |  | Abnormal 
                          blood lipids: 87% vs 72%, respectively; |   
                        |  | Higher 
                          total cholesterol; |   
                        |  | Higher 
                          low-density lipoprotein (LDL) "bad" cholesterol; |   
                        |  | Higher 
                          blood glucose. |  |   
                  |  | After 
                    4 months of follow up, HIV viral load was significantly lower 
                    among case patients compared with control subjects (2500 vs 
                    14000 copies/mL). |   
                  |  | CD4 
                    cell count and type or duration of ART, however, did not differ 
                    between the 2 groups. |   
                  |  | Several 
                    inflammation markers were elevated in patients with cardiovascular 
                    events: D-dimer, soluble VCAM-1, TIMP-1, soluble tissue factor, 
                    CD41 cells. |   
                  |  | Levels 
                    of high-sensitivity CRP, however, were similar in both groups. |   
                  |  | The 
                    immune activation markers CD38 and HLA-DR also did not differ 
                    between the groups. |   
                  |  | In 
                    a multivariate analysis adjusting for other factors, smoking, 
                    family history, D-dimer, and glucose remained independent 
                    predictors of cardiovascular disease risk. |  Based 
                on these findings, the study authors concluded, "In this 
                cohort, cardiovascular disease risk was related to traditional 
                cardiovascular disease risk factors and markers of thrombosis 
                and endothelial damage, but not to high-sensitivity C-reactive 
                protein or markers of T-cell activation such as CD38/human leukocyte 
                antigen-DR co-expression."
 Taken together, these studies shed more light on factors associated 
                with cardiovascular disease risk in HIV positive people on ART, 
                but do not offer definitive answers given that they conflict with 
                prior research.
 
 Neither of these studies, for example, saw an association between 
                cardiovascular disease and lower CD4 cell count, contradicting 
                2 
                other recent reports indicating that a decline in CD4 count 
                -- even at relatively high levels -- increased the risk of cardiovascular 
                disease and heart attacks.
 
 Investigator affiliations:
 
 Delaney study: University of Florida, Gainesville, FL; University 
                of California, San Francisco, CA; Department of Veterans Affairs, 
                San Francisco, CA; Department of Biostatistics, University of 
                Washington, Seattle, WA; Tufts Medical Center, Boston, MA; University 
                of California, Los Angeles, California, USA.
 
 Ford study: National Institute of Allergy and Infectious Diseases, 
                National Institutes of Health, Bethesda, MD.
 
 8/31/10
 ReferencesJA Delaney, R Scherzer, ML Biggs, C Grunfeld, and others (FRAM 
                study team). Associations of antiretroviral drug use and HIV-specific 
                risk factors with carotid intima-media thickness. AIDS 
                24(14): 2201-2209 (Abstract). 
                September 10, 2010.
 ES 
                Ford, JH Greenwald, AG Richterman, and others. Traditional risk 
                factors and D-dimer predict incident cardiovascular disease events 
                in chronic HIV infection. AIDS 24(10): 1509-1517 (Abstract). 
                June 19, 2010.
 
  
              
              
              
                                        |  | 
 
 
         
          |  |   
          |  |   
          | 
               
                | Stories 
                    of Success in HIV: Proven Interventions for Improving 
                    wareness, Testing, Access to Care, and Treatment of HIV in 
                    Communities of Color. |  |  
 
         
          |  |   
          |  |   
          | 
               
                | Stories 
                    of Success in HIV: Proven 
                    Interventions for Improving wareness, Testing, Access to Care, 
                    and Treatment of HIV in Communities of Color. |  |      |